Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

October 31, 2014

Conditions
Epilepsy
Interventions
DRUG

Lamictal

No comparison.

Trial Locations (13)

807-8555

GSK Investigational Site, Fukuoka

317-0077

GSK Investigational Site, Ibaraki

892-0844

GSK Investigational Site, Kagoshima

611-0042

GSK Investigational Site, Kyoto

980-8574

GSK Investigational Site, Miyagi

634-8522

GSK Investigational Site, Nara

950-1197

GSK Investigational Site, Niigata

950-2085

GSK Investigational Site, Niigata

703-8265

GSK Investigational Site, Okayama

560-8565

GSK Investigational Site, Osaka

430-8558

GSK Investigational Site, Shizuoka

110-744

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01431963 - Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy | Biotech Hunter | Biotech Hunter